CHC – The Cancer & Hematology Centers

XMT-1536-2A (Mersana)

Description:  An Open-Label, Multicenter, Dose Escalation and Expansion Modular, Umbrella Master Study of Upifitamab Rilsodotin In Combination with Other Agents in Participants with High-Grade Serous Ovarian Cancer (Upgrade)

 

Target Patient Population:   Platinum sensitive Ovarian Cancer

Study Design:  Drug is given IV every 4 week